Search Results | Blood | American Society of Hematology

1-20 of 206

Sort by

Sort Order Select

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

DOI: https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Blood (2022) 140 (Supplement 1): 3543–3545.

DOI: https://doi.org/10.1182/blood-2022-157051

Published: 2022

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

DOI: https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

DOI: https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon

Blood (2022) 140 (Supplement 1): 12125–12126.

DOI: https://doi.org/10.1182/blood-2022-165502

Published: 2022

Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 2296–2298.

DOI: https://doi.org/10.1182/blood-2022-166991

Published: 2022

Journal Articles

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

John P. Leonard, Marek Trneny, Fritz Offner, Jiri Mayer, Huilai Zhang, Grzegorz S. Nowakowski, Phillip Scheinberg, Argyrios Gkasiamis, Joanna Mikita-Geoffroy, Everton Rowe, John G. Gribben

Blood (2022) 140 (Supplement 1): 561–563.

DOI: https://doi.org/10.1182/blood-2022-158631

Published: 2022

Journal Articles

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1921–1923.

DOI: https://doi.org/10.1182/blood-2022-164692

Published: 2022

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

DOI: https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

POD24 in follicular lymphoma: time to be “wise”

John P. Leonard

Blood (2022) 139 (11): 1609–1610.

DOI: https://doi.org/10.1182/blood.2021013437

Published: 2022

Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard

Blood (2022) 139 (8): 1147–1159.

DOI: https://doi.org/10.1182/blood.2021011679

Published: 2022

Includes: Supplemental data

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

DOI: https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2021) 138 (Supplement 1): 523.

DOI: https://doi.org/10.1182/blood-2021-151266

Published: 2021

Journal Articles

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Deborah M. Stephens, Hongli Li, Louis S. Constine, John P. Leonard, Brad S. Kahl, Joo Y Song, Michael L. Leblanc, Thomas J. Fitzgerald, Sonali M. Smith, Jonathan W. Friedberg, Dan O. Persky

Blood (2021) 138 (Supplement 1): 1423.

DOI: https://doi.org/10.1182/blood-2021-147938

Published: 2021

Journal Articles

Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool

Rachael M. Andrie, John M. Burke, Ian W. Flinn, John P. Leonard, Jeff P. Sharman, Timothy A. Quill, Kristen Rosenthal, Christopher R. Flowers

Blood (2021) 138 (Supplement 1): 1922.

DOI: https://doi.org/10.1182/blood-2021-152937

Published: 2021

Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2021) 138 (Supplement 1): 2425.

DOI: https://doi.org/10.1182/blood-2021-146182

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

DOI: https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell

Blood (2021) 137 (5): 637–645.

DOI: https://doi.org/10.1182/blood.2019004753

Published: 2021

Includes: Supplemental data

Journal Articles

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Kristen Rosenthal, PhD, Jeremy S Abramson, MD MMSc, Farrukh T Awan, MD, John P. Leonard, MD, Julie M. Vose, MD MBA, Timothy A Quill, PhD, Christopher Flowers, MDMS

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-139818

Published: 2020

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-136023

Published: 2020

NARROW

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

POD24 in follicular lymphoma: time to be “wise”

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only